Premium
Niveles aumentados de CXCL‐13 en meningoencefalitis por tripanosomiasis Africana
Author(s) -
Courtioux Bertrand,
Pervieux Lynda,
Vatunga Gedeao,
Marin Benoit,
Josenando Théophile,
JauberteauMarchan MarieOdile,
Bouteille Bernard,
Bisser Sylvie
Publication year - 2009
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2009.02263.x
Subject(s) - african trypanosomiasis , immunology , chemokine , medicine , stage (stratigraphy) , cohort , cerebrospinal fluid , meningitis , gastroenterology , biology , trypanosomiasis , inflammation , pediatrics , paleontology
Summary Objectives To determine the role of the B‐cell attracting chemokine CXCL‐13, which may initiate B‐cell trafficking and IgM production in diagnosing HAT meningo‐encephalitis. Methods We determined CXCL‐13 levels by ELISA on paired sera and CSF of 26 patients from Angola and of 16 controls (six endemic and ten non‐endemic). Results were compared to standard stage determination markers and IgM intrathecal synthesis. Results CXCL‐13 levels in patients’ sera had a median value of 386.6 pg/ml and increased levels were associated with presence of trypanosomes in the CSF but not with other stage markers. CXCL‐13 levels in patients’ CSF had a median value of 80.9 pg/ml and increased levels were associated with all standard stage determination markers and IgM intrathecal synthesis. Conclusion CXCL‐13 levels in CSF increased significantly during the course of HAT. Hence the value of CXCL‐13 for diagnosis, follow‐up or as a marker of disease severity should be tested in a well‐defined cohort study.